Program
felzartamab
Also written as “Felzartamab”, “MOR202” and “TJ202 and Dexamethasone”.
Its studies are mostly in Glomerulonephritis, IGA · Multiple Myeloma · Glomerulonephritis, Membranous · Myasthenia Gravis · Graves Disease, led by 3 companies.
Drug pageFelzartamab: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogenits history only | 117 open or running | phase 3since Nov 11, 2024 | Oct 18, 2019 | Dec 1, 2026phase 3 · NCT06685757 |
| TJ Biopharmaits history only | 30 open or running | phase 3since May 14, 2019 | Jan 15, 2019 | none ahead |
| Novartisits history only | 10 open or running | phase 2since Jul 29, 2011 | Jul 29, 2011 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Jul 29, 2011.
- May 14, 2019Phase 3 study in Multiple MyelomaTJ Biopharma · NCT03952091 · 289 enrolled · China, Taiwan
- Oct 18, 2019Biogen’s first study: phase 2 study in Glomerulonephritis, MembranousNew to BiogenBiogen · NCT04145440 · 31 enrolled · United States, Australia, Belgium and more
- Dec 9, 2019Named felzartamabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, MOR202
- Jan 18, 2021Phase 2 study in GlomerulonephritisBiogen · NCT04733040 · 24 enrolled · Georgia, Germany, Greece and more
- Sep 14, 2021Phase 2 study in Kidney DiseasesBiogen · NCT05065970 · 54 enrolled · United States, Australia, Belgium and more
- Nov 4, 2021Phase 1 study in Lupus Erythematosus, SystemicTJ Biopharma · NCT05140824 · 1 enrolled · China
- Sep 26, 2023Phase 1 study in Lupus NephritisBiogen · NCT06064929 · 14 enrolled · United States, Argentina, Australia and more
- Nov 11, 2024Phase 3 study in Antibody-mediated RejectionBiogen · NCT06685757 · 132 enrolled · United States, Argentina, Australia and more
- Apr 17, 2025Phase 3 study in Glomerulonephritis, IGABiogen · NCT06935357 · 454 planned · United States, Argentina, Australia and more
- Oct 17, 2025Phase 2 study in Microvascular InflammationBiogen · NCT07219043 · 81 planned · United States, Argentina, Australia and more
- Feb 26, 2026Phase 3 study in Antibody-mediated RejectionBiogen · NCT07444489 · 201 planned · United States, Canada
- Jul 20, 2026Phase 2 study in Graves DiseaseBiogen · NCT07722546 · 60 planned · United States, Puerto Rico
- Sep 30, 2026Primary completion moved from 2031-05-28 to 2031-12-31Date moved laterphase 3 · +7 months · NCT07444489
- Oct 16, 2026Phase 2 study in Glomerulonephritis, IGABiogen · NCT07889362 · 25 planned
- Nov 10, 2026Phase 2 study in Myasthenia GravisBiogen · NCT07939802 · 75 planned
Ahead
- Dec 1, 2026Primary completion: phase 3 study in Antibody-mediated RejectionBiogen · NCT06685757
- May 31, 2027Primary completion: phase 3 study in Glomerulonephritis, IGABiogen · NCT06935357
- Jan 31, 2028Primary completion: phase 2 study in Graves DiseaseBiogen · NCT07722546
- Feb 10, 2028Primary completion: phase 2 study in Microvascular InflammationBiogen · NCT07219043
TargetBeta
“A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 ”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule
Other programs on CD38
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daratumumabrule | Johnson & Johnson | phase 4 | 44 |
| isatuximabrule | Sanofi | phase 3 | 23 |
| mezagitamabrule | Takeda | phase 3 | 11 |
| lumrotatugrule | Keymed Biosciences | phase 3 | 10 |
| Anti-CD38 Monoclonal Antibody SCTC21Crule | Sinocelltech Group | phase 3 | 5 |
| sanritatugrule | Hangzhou Sumgen Biotech | phase 3 | 5 |
| CID-103rule | CASI Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD38 Monoclonal Antibodyrule | Chongqing Genrix Biopharmaceutical | phase 2 | 1 |
| Anti-CD38 Antibody-drug Conjugate ABBV-438 | AbbVie | phase 1 | 1 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07939802Myasthenia Gravis | 2 | Not yet recruiting | Biogen | Sep 19, 2028 | 75 |
| NCT07889362Glomerulonephritis, IGA | 2 | Not yet recruiting | Biogen | Aug 13, 2028 | 25 |
| NCT07722546Graves Disease · United States, Puerto Rico | 2 | Recruiting | Biogen | Jan 31, 2028 | 60 |
| NCT07444489Antibody-mediated Rejection · United States, Canada | 3 | By invitation | Biogen | Dec 31, 2031 | 201 |
| NCT07219043Microvascular Inflammation · United States, Argentina, Australia and more | 2 | Recruiting | Biogen | Feb 10, 2028 | 81 |
| NCT06935357Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Recruiting | Biogen | May 31, 2027 | 454 |
| NCT06685757Antibody-mediated Rejection · United States, Argentina, Australia and more | 3 | Active, not recruiting | Biogen | Dec 1, 2026 | 132 |
| NCT06064929Lupus Nephritis · United States, Argentina, Australia and more | 1 | Completed | Biogen | Jun 24, 2026 | 14 |
| NCT05140824Lupus Erythematosus, Systemic · China | 1 | Terminated | TJ Biopharma | Dec 14, 2022 | 1 |
| NCT05065970Kidney Diseases · United States, Australia, Belgium and more | 2 | Completed | Biogen | Feb 6, 2023 | 54 |
| NCT04733040Glomerulonephritis · Georgia, Germany, Greece and more | 2 | Completed | Biogen | Dec 14, 2023 | 24 |
| NCT04145440Glomerulonephritis, Membranous · United States, Australia, Belgium and more | 2 | Completed | Biogen | Jan 19, 2022 | 31 |
| NCT03952091Multiple Myeloma · China, Taiwan | 3 | Completed | TJ Biopharma | Jun 30, 2024 | 289 |
| NCT03860038Multiple Myeloma · China, Taiwan | 2 | Completed | TJ Biopharma | Jan 28, 2023 | 113 |
| NCT01421186Multiple Myeloma · Austria, Germany | 2 | Completed | Novartis | Aug 2020 | 91 |
How it is read
Names in the registry
- “Felzartamab”, 9 entries
- “MOR202”, 2 entries
- “TJ202 and Dexamethasone”, 1 entry
- “TJ202, Lenalidomide and Dexamethasone”, 1 entry
- “TJ202 injection”, 1 entry
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 3 studies
- Multiple Myeloma, 3 studies
- Glomerulonephritis, Membranous, 2 studies
- Myasthenia Gravis, 1 study
- Graves Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.